Clinical Trials Logo

Mouth Diseases clinical trials

View clinical trials related to Mouth Diseases.

Filter by:

NCT ID: NCT03296410 Enrolling by invitation - Clinical trials for Hand, Foot and Mouth Disease (HFMD)

The Phase IVd of Inactivated Enterovirus 71 Vaccine

Start date: September 14, 2017
Phase: Phase 4
Study type: Interventional

Enterovirus 71 (EV71), a major pathogen causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae. Its infection occasionally leads to severe diseases and death, with central nervous system (CNS) damage. Recently, except of inactivated vaccine, several EV71 vaccine candidates have been evaluated in animals but no final results of clinical trials, such as attenuated vaccine, subunit vaccine. A formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been finished phase I, II and III clinical trials and licensed by SFDA in China at Dec. 3, 2015. Based on the results of clinical trials, the protective efficacy of inactivated EV71 vaccine is 97% against HFMD caused by EV71. The phase IV clinical trial has been carried out from July 2016. The purpose of phase IVd is to evaluated the immunogenicity and safety of the inactive EV71 vaccine within two measles attenuated live vaccine and live attenuated Japanese encephalitis vaccine at the same time point in large scale population of Chinese children (8 months old) in Guangdong Province, China.

NCT ID: NCT03281174 Completed - Clinical trials for Hand, Foot and Mouth Disease

Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine

Start date: May 20, 2017
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the 5-year Immune Persistence of Inactivated Enterovirus Type 71 (EV71) Vaccine manufactured by Sinovac (Beijing) Biotech Co., Ltd.

NCT ID: NCT03278132 Recruiting - Clinical trials for Hand, Foot and Mouth Disease

Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine

Start date: July 16, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of EV71 vaccine in infants aged 6 to 35 months old, by detecting the dynamic changes of neutralizing antibody at different time after vaccination

NCT ID: NCT03274102 Recruiting - Clinical trials for Hand, Foot and Mouth Disease

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

Start date: April 22, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine.

NCT ID: NCT03241030 Not yet recruiting - Clinical trials for Hand, Foot and Mouth Disease

Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial

Start date: August 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if sucralfate, a medication commonly used for patients with stomach ulcers, may help pediatric patients with mouth ulcers decrease their pain level and improve their ability to drink.

NCT ID: NCT03240744 Active, not recruiting - Clinical trials for Hand, Foot and Mouth Disease (HFMD)

The Phase IVc of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell)

Start date: June 22, 2017
Phase: Phase 4
Study type: Interventional

Enterovirus 71 (EV71), a major pathogen causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae. Its infection occasionally leads to severe diseases and death, with central nervous system (CNS) damage. Recently, except of inactivated vaccine, several EV71 vaccine candidates have been evaluated in animals but no final results of clinical trials, such as attenuated vaccine, subunit vaccine. A formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been finished phase I, II and III clinical trials and licensed by SFDA in China at Dec. 3, 2015. Based on the results of clinical trials, the protective efficacy of inactivated EV71 vaccine is 97% against HFMD caused by EV71. The phase IV clinical trial has been carried out from July 2016. The purpose of phase IVc is to evaluated the immunogenicity of the inactive EV71 vaccine in large scale population of Chinese children (from 6 to 71 months old) in Hubei Province, China.

NCT ID: NCT03123705 Recruiting - Oral Disease Clinical Trials

El Paso Public Health Biorepository

EPB
Start date: May 26, 2017
Phase: N/A
Study type: Observational

The prevalence of tooth decay and other oral disease are often overlooked indicators of overall public health. To improve the understanding of oral health in El Paso, the City of El Paso Health Department has teamed up with Texas Tech University Health Sciences Center El Paso in a collaborative effort to determine the factors that contribute to poor oral hygiene, and lead to cavities and periodontitis. The team will collect saliva, oral debris, leftover teeth and plaque from children and young adults to study oral infections, markers of inflammation, and other contributors to tooth decay and oral illnesses. Samples also will be stored for future investigations. This joint effort will provide a better picture of oral health in El Paso, and will define a framework for prevention, earlier diagnosis, and better treatment.

NCT ID: NCT03082365 Not yet recruiting - Clinical trials for Chronic Kidney Diseases

Oral Findings in Chronic Kidney Disease

Start date: n/a
Phase: N/A
Study type: Observational

The patients with chronic kidney disease suffer from many oral problems affecting the quality of life. The aim of our study is to assess their oral health to provide the proper management and increase their awareness

NCT ID: NCT03074188 Not yet recruiting - Clinical trials for Chronic Kidney Diseases

Prevalence of Oral Findings in Chronic Kidney Disease

Start date: n/a
Phase: N/A
Study type: Observational [Patient Registry]

There are severe deficiency of database concerning the oral health status in both pre-dialysis and end stage renal disease in Egyptian population. Our aim in the present study is to assess the oral health of the chronic kidney disease patients to increase their awareness and minimize all the possible risk factors, to achieve a proper management for all oral problems.

NCT ID: NCT03001986 Active, not recruiting - Clinical trials for Hand, Foot and Mouth Disease (HFMD)

The Phase IVb of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Children

Start date: September 2016
Phase: Phase 4
Study type: Interventional

Enterovirus 71 (EV71), a major pathogen causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae. Its infection occasionally leads to severe diseases and death, with central nervous system (CNS) damage. Recently, except of inactivated vaccine, several EV71 vaccine candidates have been evaluated in animals but no final results of clinical trials, such as attenuated vaccine, subunit vaccine. A formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been finished phase I, II and III clinical trials and licensed by SFDA in China at Dec. 3, 2015. Based on the results of clinical trials, the protective efficacy of inactivated EV71 vaccine is 97% against HFMD caused by EV71. The phase IV clinical trial has been carried out from July 2016. The purpose of phase IVb is to evaluated the safety and efficacy of the inactive EV71 vaccine in large scale population of Chinese children (from 6 to 71 months old) in Hubei Province, China.